Allergic Conjunctivitis

Overview

Allergic eye disease encompasses a spectrum of IgE- and, in chronic forms, mixed-hypersensitivity-mediated ocular surface conditions affecting an estimated 15–40% of people worldwide, disproportionately children and adolescents, and frequently coexisting with atopic dermatitis, asthma, and allergic rhinitis.¹ It ranges from mild seasonal or perennial allergic conjunctivitis to severe, potentially sight-threatening forms — vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC) — that can involve the cornea.¹

Epidemiology & Risk Factors

Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) are the most common forms and are driven mainly by type I (and in some presentations type IV) hypersensitivity reactions to environmental allergens (pollen, dust mite, animal dander).² VKC typically affects young males, often in warm climates, and tends to improve around puberty, while AKC is associated with long-standing atopic dermatitis and tends to persist into adulthood. Giant papillary conjunctivitis (GPC), a tissue-driven (type V) reaction, is associated with contact lens wear or ocular prostheses rather than environmental allergens.²

Pathophysiology

Allergic eye disease arises when environmental (or, in GPC, mechanical/foreign-body) triggers activate an IgE-mediated mast cell degranulation response, releasing histamine and other mediators that produce itching, hyperemia, and chemosis.¹ Chronic forms such as VKC and AKC involve additional, mixed type I, IVa, and IVb hypersensitivity pathways with eosinophil and T-cell-driven tissue remodeling, explaining why they can produce corneal shield ulcers and limbal changes that simple SAC/PAC never do.²

Clinical Presentation

The hallmark symptom across all forms is itching — its presence (or absence) is one of the most useful features distinguishing allergic from infectious conjunctivitis. Presentation is typically bilateral.

• SAC/PAC: itching, watery discharge, mild conjunctival injection, papillary reaction; symptoms track with allergen exposure/season
• VKC: intense itching, thick ropy mucous discharge, photophobia; giant papillae ("cobblestoning") on the upper tarsal conjunctiva, limbal Horner-Trantas dots
• AKC: chronic itching and lid changes (thickened, macerated skin), papillary reaction, higher risk of corneal scarring and cataract than VKC
• GPC: contact-lens intolerance, mucous discharge, giant papillae on upper tarsus, typically without significant itching compared to VKC/AKC

Exam Findings

• Conjunctival injection and chemosis
• Papillary reaction (fine in SAC/PAC; giant papillae/cobblestoning in VKC, AKC, GPC)
• Horner-Trantas dots (limbal eosinophilic aggregates) in VKC
• Corneal shield ulcer (in severe VKC) — a sterile, non-infectious epithelial defect from mechanical trauma of giant papillae plus toxic mediator effects
• Lid margin thickening, madarosis, and periorbital skin changes in AKC

Differential Diagnosis

• Adenoviral conjunctivitis (watery discharge but follicular reaction, preauricular node, less itching)
• Bacterial conjunctivitis (purulent discharge, papillary reaction, no significant itching)
• Dry eye disease (can overlap with and mimic mild allergic symptoms)
• Blepharitis/meibomian gland dysfunction
• Contact dermatitis from topical medications or cosmetics

Management

Diagnosis is primarily clinical, based on history and exam; ancillary testing (e.g., allergy testing) is reserved for unclear or refractory cases.¹ Management follows a stepwise approach¹:

1. Allergen avoidance, cool compresses, and preservative-free lubricating drops for all severities
2. Topical antihistamines or combined antihistamine/mast-cell stabilizer agents for mild-moderate disease
3. Short courses of topical corticosteroids for flares, particularly in VKC/AKC
4. Topical immunomodulators (e.g., calcineurin inhibitors such as cyclosporine or tacrolimus) for steroid-sparing long-term control in VKC/AKC³
5. Emerging options including monoclonal antibodies targeting key inflammatory cytokines and targeted small-molecule drugs for refractory severe disease¹

For GPC, the primary intervention is addressing the mechanical trigger — improved contact lens hygiene, more frequent lens replacement, or temporary lens discontinuation — alongside topical anti-allergy therapy.

Complications

• Corneal shield ulcer and scarring (VKC, AKC) with permanent visual impairment if untreated
• Keratoconus is associated with chronic eye rubbing seen in VKC/AKC patients
• Cataract and glaucoma from prolonged topical/systemic steroid use
• Chronic lid changes and cicatricial conjunctival scarring in longstanding AKC

Clinical Pearls

• Itching is the single most useful symptom for distinguishing allergic from infectious conjunctivitis
• VKC typically affects young males and improves around puberty; AKC is linked to atopic dermatitis and persists into adulthood
• Horner-Trantas dots and giant papillae with cobblestoning are classic VKC findings
• A corneal shield ulcer in a child with itchy eyes and giant papillae should prompt consideration of VKC, not just infectious keratitis
• Chronic eye rubbing in allergic eye disease is a recognized risk factor for keratoconus — counsel patients to avoid rubbing¹

Common Pitfalls

• Treating allergic conjunctivitis with topical antibiotics, which have no role absent secondary infection
• Using long-term topical steroids without monitoring for steroid-related glaucoma or cataract
• Missing GPC in a contact lens wearer because the presentation is mistaken for simple lens intolerance
• Failing to ask about eye rubbing, missing a modifiable keratoconus risk factor
• Overlooking corneal shield ulcers in severe VKC, which can scar and cause permanent vision loss if unaddressed